Active-ingredient Dossier

["ezetimibe"

Active-ingredient Dossier for ["ezetimibe" (cholesterol absorption inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…

What is

Ezetimibe Ezetimibe is a cholesterol absorption inhibitor.

Australian brands containing

Ezetimibe — ZIENT — ROSUZET Composite Pack — ZIMYBE — EZETROL — AKM-EZETIMIBE SIMVASTATIN — APO-EZETIMIBE — APO-EZETIMIBE/SIMVASTATIN — ARX-EZETIMIBE — ATOZET — EZALO Composite Pack — EZECREST COMPOSITE PACK — EZEMICHOL

Therapeutic areas

Ezetimibe is registered in cardiology (32 brands) and endocrinology (1 brand).

Sponsor landscape

Ezetimibe is marketed by ten sponsors: Organon Pharma, Torrent, Arrotex Pharmaceuticals, Alphapharm, Sandoz and Pharmacor.

PBS and regulatory activity

One brand containing ezetimibe has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2017–18 financial year, government expenditure on ezetimibe products was approximately $65.8 million across 1,298,565 scripts. Three brands have PBAC outcomes on record, with the latest dated 1 November 2014. One brand has an AusPAR on record, dated 20 November 2013.